Embecta Corp. misrepresented demand for the needles it makes for insulin pens, leading to a recent 58% stock drop on disappointing financials, an investor alleges.
Welcome, ladies and gentlemen, to Embecta Corp.'s Fiscal Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded, and a replay will ...
Embecta (NASDAQ:EMBC) President and CEO Devdatt Kurdikar said the company's recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and ...
Earlier this year it appeared that Embecta, a diabetes care company that spun off from BD in 2022, was finally back on track after a rocky 2025. The Parsippany, NJ-based company’s fiscal ...
Welcome, ladies and gentlemen, to Embecta Corp.'s fiscal second quarter 2025 earnings conference call. At this time, all participants have been placed in a listen-only mode. Please note that this ...
Embecta (NASDAQ:EMBC) President and CEO Devdatt Kurdikar said the company’s recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results